Evidence map›Paper›PMID 42064089›Full record

ReviewFrontiers in immunology2026

Cul5: immune cell function and therapeutic potential.

Siera A Tomishima, Paula M Oliver

Abstract readReview
In one paragraph

Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Siera A TomishimaDepartment of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States.
Paula M OliverDepartment of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States.

Funding

A Cul5 E3 ubiquitin ligase complex that prevents allergic asthmaR01AI148240 · NIAID · CHILDREN'S HOSP OF PHILADELPHIA · PI OLIVER, PAULA MARIA · 2020 to 2024
$2.7M
NIAID NIH HHS R01 AI148240
6 · The paper itself

Abstract

A primary function of immune cells is to protect against pathogens. To do this, cells surveil the body using receptors on their surface that can detect antigens from the invading organism or sense cytokines that act as danger signals. These receptors activate transcriptional programs that allow the cells to mount a response appropriate for the pathogen detected. To rapidly switch into an activated state, or to return to homeostasis, immune cells must initiate and terminate signaling pathways. Immune cells use post-transcriptional regulatory processes as one means to quickly change cellular behavior. This can be mediated by kinases and phosphatases that turn signaling pathways on or off. An additional important mechanism for downregulating immune effector cells is mediated by E3 ubiquitin ligases (E3s), which promote the degradation of receptors and their downstream signaling mediators. Ubiquitin ligases are enzymes that add ubiquitin modifications to specific protein substrates, targeting them for degradation via recruitment to the proteasome or altering their localization and activity. Cullin 5 (Cul5) is a scaffold protein that forms a multiprotein complex called Cullin Ring Ligase 5 (CRL5). To select substrates, CRL5 engages with Suppressors of Cytokine Signaling (SOCS)-box containing proteins. Collaborating with different SOCS-box containing substrate receptors allows Cul5 to promote selected protein degradation in a cell type- and context-specific manner. CRL5 and SOCS-box containing proteins regulate cytokine signaling to control proliferation, differentiation and immune functions in various cell types. Here, we give an overview of the ubiquitin proteasome system (UPS) and review new insights that advance our understanding of how Cul5 and CRL5 complexes regulate immune cell function. We then discuss ongoing therapeutic strategies that target various components of the UPS, and highlight the potential for new therapies targeting CRL5 for a range of diseases.

Indexed as

Cullin ProteinsAnimalsHumansProteasome Endopeptidase ComplexSignal TransductionSuppressor of Cytokine Signaling ProteinsUbiquitinationUbiquitin-Protein LigasesCullin ProteinsProteasome Endopeptidase ComplexSuppressor of Cytokine Signaling ProteinsUbiquitin-Protein Ligasescullin 5E3 ubiqitin ligaseimmune cellsSOCS proteinsubiquitin proteasomal system

Identifiers

PMID42064089
PMCPMC13124974

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.